Background: Policies for health technologies such as medical devices are essential and contribute to improved quality of healthcare. The regulation, assessment, and management represent important functions of medical devices. Insufficiently developed interactions between these functions impact the quality of delivered healthcare. To date studies lack to analyse these functions in a broad way. The aim of this study is to analyse the regulation, assessment, and management of orthopaedic medical devices in Mexico and how they shape healthcare. Methods: This qualitative study included 42 stakeholders involved directly or indirectly in the regulation, assessment, or management for orthopaedic medical devices in Mexico. Results: The fragmentation of responsibilities for medical device functions may be a central aspect of our findings concerning challenges reported by interviewees. Strengthening technovigilance based on improved reporting across health care institutions emerged as pathway to improve medical device regulation. With regard to improving the medical device assessment, a comprehensive update of the standard list represents a relevant opportunity. Integrating advanced quality attributes into procurement processes regarding decision-making, purchasing strategy, and procurement agent is needed to fostering the management. Conclusions: This study provides a broad analysis of medical device functions within a health system and highlights in this specific context how improvements might be achieved. It addresses a broad range of interest groups represented by policy makers, health service providers, managers and administrators of healthcare facilities, and doctors with an interest in health technologies. In this paper we highlight important themes that influence outputs and outcomes of the regulation, assessment, and management and discuss strategies in fostering these areas. To date, the regulation, assessment, and management of medical devices are rarely analysed in a broad way, even though these functions importantly contribute to the successful implementation of health technology policies. The quality of delivered healthcare is influenced by the performance between and within these functions. In Mexico, little discussion has been raised on challenges of the regulation, assessment, and management of medical devices. Changes to current processes and practices can improve outputs and outcomes of these functions and positively influence the quality of delivered healthcare. Stakeholder involvement and commitment is essential to this.
Background
Policies for health technologies such as medical devices are essential to assure equitable access to high quality and affordable devices and their appropriate use and thus contributing to improved quality of care [1] . The World Health Organization (WHO) emphasizes the importance of developing and implementing health technology policies within the context of a national health plan. WHO indicated that 34% of 145 countries have a health technology national policy in place that is part of the national health programme [2] . Mexico is one of these countries and has established several government agencies (Table 1 ) and defined regulations that support policies for health technologies. This is key to organize and support, and strengthen important functions for medical devices. These functions are the regulation, assessment, and management of medical devices and compose important areas of the Medical Device Life-Cycle (MDLC) ( Table 2 ) and support health care delivery at different organizational levels within the health system.
Besides the development and implementation of health technology policies, WHO emphasizes the importance of the commitment for, and realization of a continuous improvement plan within and between the areas of the MDLC in order to strengthen the implementation of national health technology policies and to contribute to improved health [1] . This can be achieved when necessary interactions between these areas are established because of their interdependence. To date, there are indications of questions regarding different attributes of the MDLC for orthopaedic high-risk medical devices (HRMDs) in Mexico and their influence on clinical practice and thus on the delivered quality of health care [3] [4] [5] [6] [7] . HRMDs are implanted in the human body (such as a knee joint implant) and are therefore recommended subject to the highest level of pre-market and postmarket regulation [8] . To date, little is known how these attributes affect outputs and outcomes of the MDLC and its meaning for quality of health care. The articles 83, 179 and 180 of the current Medical Device Regulation of Mexico indicate that there are no specific regulations for HRMDs differentiating them from lower risk medical devices.
The Mexican health system is a complex system with multiple actors encompassing a public private mix of hospital providers [9] . The national health care system is decentralized with planning, management, and regulatory authority shared at the federal and state-level [10, 11] . In Mexico, the different sub-systems of health care (social security and state-level health care systems (SESA)) are disconnected and the level of health care and outcomes between these sub-systems varies [12] . This leads to a fragmentation of responsibilities with regard to the MDLC areas, which might affect the ability of policymakers to comprehensively oversee the MDLC in Mexico.
The aim of the present study is to analyse challenges of the regulation, assessment, and management of orthopaedic medical devices in Mexico and their impact on outputs and outcomes of the MDLC. Further, we discuss possible ways forward in fostering the regulation, assessment, and management and their influence on the quality of delivered health care.
Methods
Our research approach is based on a working framework (Fig. 1) , which is guided by two considerations: (i) MDLC represents key functions for medical devices and as a whole it is a functional system contributing to improved health, and (ii) important stakeholders related to the MDLC exert their influence at the macro level (regulation and policy mechanism), meso level (public health care institutions and care provider facilities), and micro level (healthcare professional and patient). The framework guided the data collection and analysis. This research is part of a larger study to investigate the relation between the regulation, assessment and management of orthopaedic HRMDs in Mexico and their impact on clinical procedures.
Study population and recruitment
The study was done in Mexico. We identified and recruited participants for interviews by searching listings from the governmental offices, public sector, orthopaedic specialists (public and private sector), organisations, medical device supplier. We used a maximum variation sampling [13] to recruit key stakeholder based on three sample criteria: (1) stakeholders influencing MDLC areas; [14] stakeholders influencing between MDLC areas; and [14] stakeholders that have potential to influence MDLC areas in the future.
Data collection
In total 42 interviews were conducted between April and May 2016 by the principal investigator and a research assistant. The principal investigator and a research assistant conducted interviews in Spanish. We used a file-naming system and anonymized interviewees by generating a list of archival numbers. We used faceto-face interviews (n = 39) and phone interviews (n = 3) ( Table 3 ). All interviews were audio recorded, transcribed, and reviewed again by the principal investigator with the exception of one interview owing to employer requirements and we used an interview protocol. The interview guide (Additional file 1) was previously validated among a small group of persons familiar with medical device regulation, assessment, and management.
Data analysis
To assess views of stakeholders on challenges of and possible ways forward in fostering the MDLC areas, we thematically analysed the transcripts [15] . MAXQDA software (version 11, VERBI GmbH) was used to aid data management. To describe the views of stakeholders regarding challenges, first, we closely read each transcript. Second, we deductively coded one-third of the transcripts based on the themes of our conceptual framework and inductively coded for new themes. Third, we clustered codes into categories, revised the final list of codes and categories. Fourth, we systematically applied coding to all transcripts and drew on important themes. The principal investigator analysed all primary data alone, which implies a limitation of validity check. To integrate the views of stakeholders regarding possible ways forward in fostering MDLC areas into the discussion of the present study we analysed them in the context of the key findings, the findings of our previous studies and the results of our background research on current medical devices reforms and policies.
Results
The results of this study are structured along the areas regulation, assessment, and management and summarized by their importance in Table 4 . Illustrative quotations are presented in Table 5 .
Area of regulation: Reporting of adverse events and complications during clinical practice
There was some degree of consensus among interviewees that technovigilance activities (post-market surveillance of approved medical devices) should be strengthened across all levels of health-care delivery, but mainly at the meso level (health care institutions). Further, these activities may contribute to a wider scope of decision-making such as purchasing decisions. In Mexico, monitoring activities for HRMD safety and performance take place under the supervision of the Technovigilance department of the Federal Commission for the Protection against Sanitary Risks, which relies on the reporting of health care institutions. Interviewees noted that the reporting of health care institutions is sub-optimal. The federal Technovigilance department encompasses decentralized departments of the SESA and the responsible technovigilance actors at the social security institutions. Few interviewees thought that they did not see significant advances in technovigilance activities since its introduction in 2013 and thought that it was not implemented sufficiently. They noted that technovigilance often only exists on paper rather than in daily practice. Interviewees provided different reasons for this. Many interviewees thought that monitoring the safety and performance of HRMDs was insufficiently developed for a long time. Some interviewees from the macro level noted that a major difficulty to improve technovigilance was to coordinate the different subsystems of the Mexican health system. They stated that the commitment of users and suppliers to inform technovigilance officers about adverse events and incidents is irregular and activities at the meso level provide insufficient guidance to HRMD users. Intra-operative complications are negative outcomes of using HRMDs during surgery and accompanying services such as instruments, implant sets, surgical technique, or technical assistance of supplier during surgery. Some interviewees stated that users report intraoperative complications to procurement administrators so that they can be managed in the context of service and delivery contract duties. But some noted as well that managing information about these complications is essential as these failures may influence medical outcomes in the long-term, considering their nature and frequency. Further, few interviewees noted that the awareness of the involved stakeholders about how reporting can contribute to decision-making at the meso and macro levels is low. Some interviewees thought that establishing an effective reporting system and infrastructure may contribute to the strengthening of the evidence of intraoperative complications, which is contributing to technovigilance.
Area of assessment: Decisions about the eligibility of HRMDs
Many interviewees indicated that the eligibility of orthopaedic HRMDs was not regulated thoroughly enough. Some interviewees noted that the current version of the standard list for orthopaedic and osteosynthesis medical devices still included several obsolete technologies or misleading descriptions. They noted that a major difficulty is that, by law, these changes to the standard list require formal modification requests from, e.g., a social security institution or a medical device supplier. Neither the inter-institutional committee nor the General Council of Health can implement such changes independently. Some interviewees thought that solving these problems of eligibility requires, among else, strong governance and improvement plans. They noted that updating the standard list is important, but only as a prerequisite rather than as a sustainable step in improving the post-market regulation of HRMD eligibility. Despite the national standard list (macro level), each public health institution manages its own standard list for health supplies (meso level). Few interviewees thought that it was necessary to unify these standard lists into one single standard list.
Area of management: Procurement decision-making, purchasing strategy, procurement agent competencies
In Mexico, decision-making is strongly guided by conformity checks of HRMD specifications (e.g. material, mechanical characteristics, dimensions) and lowest-price offers [3] [4] [5] . Many interviewees thought that the applied procurement regulations and practices in use have not advanced over the past years. Some interviewees noted that decision makers had difficulties understanding differences between medical device brands in terms of their clinical performances (e.g. implant survival rate, primary stability of implant, implantation based on surgical technique). They thought that improved and systematic risk assessment of HRMDs might elucidate risks in a wider scope with the potential to lead to a more thorough use of public budgets, such as Health Technology Assessments (HTA) at hospital level. They noted that medical devices are currently not assessed sufficiently such as implant survival rate. Some interviewees thought that integrating aspects of quality more thoroughly could contribute to the changing of decision-making criteria. Some interviewees thought that solving deficiencies of specific purchasing strategies could positively influence procurement outcomes and the quality of services provided, respectively. They noted that nowadays outcomes are affected by sub-optimal supplier performance; suppliers are often unable to respond timely with material and technical support to contract assignments because they are often contracted shortly before the contract period started. Many interviewees noted that the increasing use of the bundling of services through Servicios integrales requires more quality control. A Servicio integral encompasses a range of disposable and nondisposable medical products used for surgery and merges them into one supplier service. Some interviewees noted Macro level "… we explained to the health professionals that finally they are the ones who complain about a product that fails and that the product does not provide the required results. However, me as authority how can I take notice about that < complaints > if they < end-users > dont make notifications, if they don't report failures than I cannot find it out and if I don't find it out I cannot react, if I dont react the things stay as they are."
Macro level
"… not only the bad quality of the materials but also the bad service which they provide for technical assistance… This type of complaint converts into an internal report and stays there, I am sorry that I have to say that."
Micro level "… do you believe that the authorities of the institutions don't know the needs that exist?"
Area of assessment: Decisions about the eligibility of HRMDs "… we noticed the extremely poor culture of science that was present in the area of technology assessment."
Macro level
"As a result of poor regulation every buys what he wants and we complain about lots of things…"
Meso level "A lot of people said as well that we should skip the institutional standard lists."
Macro level
Area of assessment: Decisions about the eligibility of HRMDs "I believe that the first error of the pseudo transparency of implant procurement is that they buy at the lowest price."
Macro level "It's incredible that a surgery has to be cancelled because the supplier did not arrive with the material … Which economic penalty can compensate this damage to the patient…"
Micro level "… a serious problem of the servicio integral is that they decide which brands they include in their service packages … Cheaper products so that they make more profit."
Supplier "… there are constant changes, when a new person comes sometimes he dosent has sufficient preparation to realize a tender."
Micro level
"… the procurement agent knows the standard list but little about the basics of a joint implant."
Supplier that this facilitates the public sectors' administrative processes, but it also removes the procurement administrators' control of the final selection of the orthopaedic HRMD brand. Some interviewees explained that decision makers underestimated the role played by the procurement agent who is concerned with administrative tasks and processes to support needs assessment or analysing supplier offers. They thought that procurement agents should have minimal professional skills underlined by specific certificates so that they were able to understand clinical needs better and to not affect negatively procurement results. Many noted that administrators often have difficulty understanding the clinical needs of users and underestimate the consequences of their decisions about clinical procedures. Some of the interviewees mentioned the importance of continuous training; it could contribute to changing a purely administrative passive support into a more integrated service function. Until now, little attention has been paid to the continuous education of procurement agents.
Discussion
Interview participants identified important challenges in relation with the MDLC areas in Mexico (affecting policy outputs and outcomes), which might influence the quality of care. With regard to regulation, reporting of adverse events was perceived as the most important challenge; assessment is challenged by several obsolete or wrongly described technologies in the standard list for orthopaedic and osteosynthesis products; while integrating advanced quality attributes into procurement processes was a mayor issue raised regarding the area of management. According to interviewees, subjacent to these challenges is the fragmentation of responsibilities with regard to the MDLC areas and the disconnection of the several sub-systems of health care. Overall we found that this causes a lack to support well-integrated MDLC areas and translates into sub-standard outputs and outcomes. In consequence the multiple actors have difficulties to improve the quality of delivered health care. Possible ways forward in fostering the regulation, assessment, and management of medical devices in Mexico are:
Regulation: Strengthening technovigilance Assessment: Updating the Standard list for orthopaedic and ostheosynthesis medical devices Management: Introducing a decision-making guidance with focus on quality attributes for decision-making, purchasing strategy, and procurement agent competencies We found that strengthening technovigilance can potentially improve outputs and outcomes of the regulation in the following ways: It can influence the compliance of involved stakeholders (e.g. for post-market reporting) and contribute to improved quality. To strengthen technovigilance three aspects may be considered: (i) including technovigilance tasks in the requirement catalogue of hospital certifications, (ii) fostering inter-institutional technovigilance guidelines, and (iii) implementing a technovigilance code of conduct (for hospital providers, health-care workers and suppliers). Further, in the literature we found that countries having a well-functioning post-market surveillance system complement their regulatory tasks by integrating specific approaches into the regulators' work to evaluate health technologies or define benchmarks for quality standards [16, 17] .
We found that introducing a guidance focusing on quality attributes can improve outputs and outcomes of the assessment and management in the following ways: It can enrich decision-making by knowledge about clinical longterm performance of medical devices, and improve clinical outcomes and cost-effectiveness. Further, it can influence operational rules and guidance for orthopaedic HRMDs and contribute to improved quality of delivered of health care. To introduce stronger quality attributes the following aspects may be considered: (i) introducing quality benchmarks for orthopaedic procedures (e.g. survival rate requirements) and establishing survival rate expectations for new listed technologies; and (ii) Introducing HTA at the level of hospitals or purchasing groups that allow to integrate a risk assessment of orthopaedic HRMDs into decision-making. Further, we found that in the United Kingdom the National Institute for Health and Care Excellence defines recommendations including benchmarks, e.g., for the quality of hip prostheses, as "the new joint should work well in at least 95% of hip replacements over 10 years, instead of the current 90%" [18] . These recommendations contribute to the maximization of clinical outcomes and costeffectiveness and can be reflected in risk assessments for orthopaedic HRMDs [19, 20] . Understanding the role played by decision makers concerning the absence of high-quality data is an important insight into procurement activities such as purchase and supply [21, 22] .
We found that enhancing competencies of procurement agents can improve outputs and outcomes of the management phase in the following ways: It can influence operational rules and guidance for orthopaedic HRMDs and contribute to improved health care delivery. To enhance competencies of procurement agents the following aspects may be considered: (i) Updating requirements for core competencies needed for procurement agents, and (ii) integrating procurement agents into evaluation tasks of outcomes of applied purchasing strategies such as Integral Services. Further, in other countries the orthopaedic specialist still has high decision-making autonomy, which alleviates some responsibility from the procurement agent. Thus we had difficulties to find examples emphasizing the aspect of enhancing competencies of procurement agents.
This study highlights important findings in a national context. However, some issues identified by the present study do emerge in a similar way in other health systems as well. For instance, the Swiss healthcare system is characterized by a decentralized structure with large decision-spaces at cantonal (regional) level. However, the healthcare legislative allows for initiatives and programmes that benefit the whole of the country so that the fragmentation of responsibilities regarding the MDLC areas is contained. For instance, Switzerland did face similar problems as Mexico relating to post-market surveillance regarding the level of clinical long-term data available for orthopaedic medical devices. As a solution to this a national arthroplasty registry, which is overseen by the National Association for Quality in healthcare facilities, was introduced. This was only possible by substantial commitment of the different parties concerned by the registry such as national and local policy makers, insurances, the associations of orthopaedic surgeons and the medical device industry. The Mexican healthcare system is characterized by various sub-systems of health service provision. The healthcare legislative limits the authority of the MoH to establish initiatives or programmes regarding medical devices that could benefit the whole sector. For instance, the social security institutes apply their own regulations for the assessment and management of medical devices. We found that this fragmentation of responsibilities influences the ability of policy makers to carry forward promising ways to improve outputs and outcomes of the MDLC areas. However, the relation between the MoH and sub-systems is in a transition and some recent advances demonstrate that [12, 23, 24] . For instance, policy makers agreed on an information technology system that enables them to consolidate relevant key data across the different sub-systems at federal level. This system that is supported by all sub-systems is called the National System of Basic Information in Healthcare (SINBA) [26] . It is under the supervision of the National Department for Information in Health of the Ministry of Health and can significantly contribute to improvement. SINBA is still in progress but expected to be launched by end of 2017. It represents an information strategy for capturing and consolidating data across the different sub-systems. As next steps for the policy making process in Mexico we recommend to take into account that the integration of stakeholders such as the National Academy for Medicine, the associations of orthopaedic specialists, and the associations of the medical device industry is important as they can contribute to the establishment of initiatives and programmes to improve the MDLC areas, and help to partially overcome the fragmentation of responsibilities. An important next step is the strengthening of Technovigilance.
Limitations of the study
For this study, we used non-random sampling, which does not necessarily guarantee the sample being representative for the population of person involved in the regulation, assessment, and management of medical devices in Mexico. However, this study includes 42 stakeholders working in the field of regulation, assessment, management or clinical practice. Thus it covers different groups of stakeholders in terms of expertise. We were not granted permission to include employees of the Mexican Institute of Social Security, which is the largest social security institution in Mexico, because of its research study approval policies. Further, the sampling is based on a maximum variation strategy and may constitute a selection bias. The interpretation of the findings that served to define possible ways forward to fostering the regulation, assessment, and management of orthopaedic medical devices is a subjective process.
Conclusions
This study provides a broad analysis of medical device functions within a health system and highlights in this specific context how improvements might be achieved. It addresses a broad range of interest groups represented by policy makers, health service providers, managers and administrators of healthcare facilities, and doctors with an interest in health technologies. In this paper we highlight important themes that influence outputs and outcomes of the regulation, assessment, and management and discuss strategies in fostering these areas. To date, the regulation, assessment, and management of medical devices are rarely analysed in a broad way, even though these functions importantly contribute to the successful implementation of health technology policies. The quality of delivered healthcare is influenced by the performance between and within these functions. In Mexico, little discussion has been raised on challenges of the regulation, assessment, and management of medical devices. Changes to current processes and practices can improve outputs and outcomes of these functions and positively influence the quality of delivered healthcare. Stakeholder involvement and commitment is essential to this.
To overcome the impact of the fragmentation in the Mexican health system, policy makers could orientate on what other countries with a similar complex health sector are doing to improve outputs and outcomes of the MDLC such as the United States, Germany, or Switzerland. An important advance is that the Ministry of Health is developing a new policy that targets to strengthen technovigilance across all sub-systems. This is a promising way forward in fostering the regulation and to fully engage all stakeholders. This study may contribute to show to policy makers additional ways forward in fostering the regulation, assessment, and management towards improved quality of delivered health care. 
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